3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Glioblastoma
41
Glioma
18
Brain Neoplasms
14
Astrocytoma
11
Neuroblastoma
10
Gliosarcoma
10
Neoplasms
8
Sarcoma, Ewing
7
Rhabdomyosarcoma
6
Recurrence
5
Oligodendroglioma
5
Sarcoma
4
Medulloblastoma
4
Neoplasm Metastasis
3
Diffuse Intrinsic Pontine Glioma
3
Wilms Tumor
2
Small Cell Lung Carcinoma
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Melanoma
2
Lymphoma, Follicular
2
Hepatoblastoma
2
Central Nervous System Neoplasms
2
Spinal Cord Neoplasms
1
Somatostatinoma
1
Rhabdoid Tumor
1
Refractory Solid Tumors
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Interventions
Paclitaxel
22
Bevacizumab
20
Carboplatin
19
liposomal doxorubicin
14
Specimen Handling
14
Magnetic Resonance Spectroscopy
13
olaparib
12
Topotecan
9
Gemcitabine
9
Biopsy
8
pembrolizumab
7
Taxes
6
Immunoglobulin G
6
Disulfides
6
niraparib
4
mirvetuximab soravtansine
4
cediranib
4
Doxorubicin
4
oregovomab
3
Nivolumab
3
Cyclophosphamide
3
sarilumab
2
rucaparib
2
cemiplimab
2
berzosertib
2
adavosertib
2
Oxaliplatin
2
Docetaxel
2
Cisplatin
2
Biosimilar Pharmaceuticals
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Temozolomide
×
90 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled